Liraglutide-¹³C₅,¹⁵N TFA 

Liraglutide-¹³C₅,¹⁵N (tetraTFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014)^[1]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus^[2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3757.16 (free acid)

C₁₆₇¹³C₅H₂₆₅N₄₂¹⁵NO₅₁._xC₂HF₃O₂

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-{Val-13C5,15N}-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly (TFA salt)

HAEGTFTSD-{Val-13C5,15N}-SSYLGQAA-{Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]}-EFIAWLVRGRG (TFA salt)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]